

Pelashield™

SAM™ Antimicrobial Technology

PainGuard™ with Lidocaine

Managing your **PAIN POINTS** just got easier



Protecting
burns & wounds
from infection risk



Initiating
acute pain relief



Simplifying
topical analgesic
dosing and application



Reducing
pain-related
discharge delays

Experience the **POWER** of PainGuard™

The **first** and **only** wound care matrix to incorporate broad spectrum antimicrobial silver **PLUS** lidocaine to manage both infection risk and pain.

2 important considerations
in wound healing

managed
with just

1 Solution

How it **Works:**

- ✓ **SAM™ Technology**, a porous matrix of **bioresorbable** polymers, **conforms to micro-textures** of the wound^{1,2} and facilitates a moist and cytophillic wound-healing environment^{1,2} that allows for cells to attach, adhere, migrate and proliferate^{1*}
- ✓ The matrix contains **ionic** and **metallic silver** at a low, non-toxic level, providing at least **72 hours of sustained, 99.99% reduction in microbial burden**^{3*}
- ✓ With the added benefit of **PainGuard™**, the matrix delivers a **unit-dose, uniform release of lidocaine** comparable to a **4%** lidocaine ointment,⁴ providing accurate administration and preventing side effects from excessive dosages of uneven gels or ointments
- ✓ **>80% release of lidocaine within 30 minutes**⁴ provides immediate, **acute pain relief** across a wide range of wound types, including **surgical, burn, donor site, trauma**, and **chronic wounds**. It is especially **beneficial during painful excisions** and also procedures such as **dressing changes** and **debridement**.

The **IMPACT** of Infection & Pain

Infection is one of the leading causes of burn injury death and complications in the burn unit:⁵

- ✓ Infection precedes **83%** of patients who developed multi-organ dysfunction⁵
- ✓ **75%** of burn patient mortality is due to infections⁵
- ✓ Infection is a significant predictor of **skin graft loss**⁶⁻⁹
- ✓ With complications, a severe burn can cost more than **\$10 million** to treat successfully.⁵

Pain Management is vital for Burn Patients:

- ✓ They can experience intense pain during daily therapeutic procedures, including wound care dressing changes, and debridement¹⁰
- ✓ Without effective pain management, they endure acute pain as well as secondary complications such as long-term anxiety, post-traumatic stress, and delayed wound healing due to elevated pain levels¹⁰




Address your **Pain Points** with Pelashield™ PainGuard™

- ✓ **Relieve initial pain** and **provide antimicrobial protection BEFORE or AFTER** a procedure with a dose-controlled, **1-step solution**
- ✓ **Help improve patient discomfort** for better compliance to **accelerate healing**
- ✓ **Facilitate timely patient discharge**

Your **One-Solution Answer** for managing infection risk and pain in wounds.

Product Size (cm)	Product Size (in)	Product Number / Reference	Product Description (sterile, individually packaged)	Total (cm ²)	Total Lidocaine Quantity per Piece (mg)
10 × 23 cm	3.9 × 9.1 in	PSPG 1023	Pelashield™ PainGuard™, 10 × 23 cm	230 cm ²	92.0 mg
15 × 15 cm	5.9 × 5.9 in	PSPG 1515	Pelashield™ PainGuard™, 15 × 15 cm	225 cm ²	90.0 mg

Pelashield™ PainGuard™ contains 0.4 mg/cm² lidocaine; a single dose of lidocaine should not exceed 300 mg, or 4.5 mg/kg¹¹



- ✓ **Easy to open and use**
- ✓ **Needs NO refrigeration**
- ✓ **2 year shelf life**

Customer Service:

Customer Care email:
cs@Imbedbio.com

Phone:
888.472.9898

Hours:
8am - 5pm CT

REFERENCES: 1. Agarwal A, et al. Surfaces modified with nanometer-thick silver-impregnated polymeric films that kill bacteria but support growth of mammalian cells. *Biomaterials*. 2010;31(4):680-90. 2. Study 15T. 41113. 02, Systemic Toxicity, Local Tissue Response, and Wound Healing Study of Microlyte Ag. Following Repeated Treatment to Full-Thickness Wounds in Rats – 28 Days. Data on file, Imbed Biosciences. 3. U.S. Food and Drug Administration. 510(k) Summary K211943: Microlyte Ag/Lidocaine. FDA. gov. Published July 2021. Accessed August 9, 2025. https://www.accessdata.fda.gov/cdrh_docs/pdf21/K211943.pdf. 4. 19-01 Report, Silver-Lidocaine Release Profiles of Microlyte Ag/Lidocaine Wound Dressing (DOC-907). Data on file, Imbed Biosciences. 5. Gauglitz GG, Shahrokhi S, Williams FN. Burn wound infection and sepsis. UpToDate. Updated March 18, 2025. Accessed August 9, 2025. <https://www.uptodate.com/contents/burn-wound-infection-and-sepsis>. 6. Turissini JD, Elmarsafi T, Evans KK, Kim PJ. Major Risk Factors Contributing to Split Thickness Skin Graft Failure. *Georgetown Medical Review*. 2019;3(1). 7. Høgsberg T, Bjarnsholt T, Thomsen JS, Kirketerp-Møller K. Success rate of split-thickness skin grafting of chronic venous leg ulcers depends on the presence of *Pseudomonas aeruginosa*: a retrospective study. *PLoS One*. 2011;6(5):e20492. 8. Abdulmughni LA, Al-Sanabani JA, Gilan WM, Issa MA, Jowah HM. Split-thickness skin graft outcomes and associated risk factors in patients with skin defects at Al-Gumhour hospital, Sana'a, Yemen: a prospective observational study. *BMC Surg*. 2025 Jul 9;25(1):292. 9. Hanson-Viana E, Rojas-Ortiz JA, Rendón-Medina MA, Luna-Zepeda BL. Bacterial fluorescence imaging as a predictor of skin graft integration in burn wounds. *Burns*. 2024 Sep;50(7):1799-1811. 10. Kornhaber R, McKittrick A, Rossiter R, Cleary M. Pain experiences in adult burn survivors during rehabilitation and recovery: A qualitative systematic review. *J Burn Care Res*. Published online March 21, 2025. doi:10.1093/jbcr/iraf031 11. <https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=0c0799dec-effd-4d8a-9874-8ca0b31e54d0&type=display>

* As demonstrated in vitro

©2025 Imbed Biosciences, Inc. All rights reserved. P/N 46105 Rev.0

